Background Influenza vaccine effectiveness (VE) can vary by type and subtype. Over the
past decade, the test-negative design has emerged as a valid method for estimation of VE …

Objectives Summary evidence of influenza vaccine effectiveness (IVE) against hospitalized
influenza is lacking. We conducted a meta-analysis of studies reporting IVE against …

The monoclonal antibody nirsevimab was at least 70% effective in preventing
hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory …

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …

Background Increased illness due to antigenically drifted A (H3N2) clade 3C. 3a influenza
viruses prompted concerns about vaccine effectiveness (VE) and vaccine strain selection …

Influenza viruses undergo frequent antigenic changes. As a result, the viruses circulating
change within and between seasons, and the composition of the influenza vaccine is …

Background: The test-negative design is an increasingly popular approach for estimating
vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test …

Background To date, no study has examined influenza vaccine effectiveness (IVE) against
laboratory-confirmed influenza-associated hospitalizations during pregnancy. Methods The …

Background Following universal recommendation for use of 13-valent pneumococcal
conjugate vaccine (PCV13) in US adults aged≥ 65 years in September 2014, we conducted …

Abstract Background. The 2014–2015 influenza season was distinguished by an epidemic
of antigenically-drifted A (H3N2) viruses and vaccine components identical to 2013–2014 …